|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | AstraZeneca |
|---|---|
| Information provided by: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT00564499 |
Purpose
A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners
| Condition |
|---|
|
COPD |
| Study Type: | Observational |
| Study Design: | Case-Crossover, Prospective |
| Official Title: | A Scientific Research Program to Evaluate the Efficacy of SYMBICORT® 320/9μg in the Treatment of COPD in Real Life Environment by General Practitioners |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | SRP-RB-COPD-2005/1 |
| Study First Received: | November 26, 2007 |
| Last Updated: | April 3, 2009 |
| ClinicalTrials.gov Identifier: | NCT00564499 History of Changes |
| Health Authority: | Belgium: Federal Agency for Medicinal Products and Health Products |
|
COPD Symbicort General Practitioners |
|
Respiratory System Agents Lung Diseases, Obstructive Symbicort Respiratory Tract Diseases Therapeutic Uses |
Lung Diseases Anti-Asthmatic Agents Pharmacologic Actions Pulmonary Disease, Chronic Obstructive |